Yahoo Finance

ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation ...

MINNEAPOLIS, Sept. 16, 2025 /PRNewswire/ -- ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic migraine, today announced ...
Business Insider

ShiraTronics Announces Landmark Achievement: World's First Implant of its Innovative Chronic Migraine System

MINNEAPOLIS, Dec. 19, 2023 /PRNewswire/ -- ShiraTronics, Inc., a trailblazing clinical-stage medical device company, today announced a landmark achievement with the successful implantation of its ...
The Business Journals

ShiraTronics begins clinical trials, raises $5M for chronic migraine relief

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Brooklyn Park-based ShiraTronics ...
Taiwan News

ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine

This latest round of funding will support ShiraTronics' recently launched U.S. Food and Drug Administration (FDA)-approved pivotal trial, the RELIEV-CM2 Clinical Study, a multi-center, blinded, ...
Mena FN

Shiratronics Raises $66 Million In Oversubscribed Series B Financing To Advance Pioneering Treatment For Chronic Migraine

(MENAFN- PR Newswire) Implantable Neuromodulation System Shows Early Promise in Improving Patient Quality of Life by Reducing Monthly Headache Days and Severity of Migraine Attacks MINNEAPOLIS, Oct. 9 ...